While only CCND1, AXL, CDKN2A, and EZH2 have significant protein level expression in the tumor tissue and were predicted to be targeted with various drugs such as palbociclib, methotrexate, bortezomib and fluorouracil, sorafenib, dasatinib, carboplatin, paclitaxel, gemcitabine, imatinib, doxorubicin, and vorinostat which needs to be further investigated via pre-clinical/clinical studies to establish its clinical significance. This evidence concerns the gene CDKN2A and neoplasm.